Search
Skip to Search Results- 4Bubela, Tania
- 2Knowles, Lori
- 2McCabe, Christopher
- 1Biesecker, Barbara
- 1Borry, Pascal
- 1Carroll, June C.
-
Challenges for Intellectual Property Management of HIV Vaccine-Related Research and Development: Part 1, The Global Context
Download2014-11-14
The HIV/AIDS pandemic is one of the defining issues of the 21st century. AIDS is the leading cause of death in Africa and the fourth-leading cause of death globally. UNAIDS estimated that 33.2 million people were living with HIV in 2007. More than twenty million people have already died from AIDS...
-
Challenges for Intellectual Property Management of HIV Vaccine-Related Research and Development: Part 2, The Canadian Context
Download2014-11-14
Patten, San, Bubela, Tania, Knowles, Lori
This paper builds upon the key issues identified in Part One of this series of two papers on“Challenges for Intellectual Property Management of HIV Vaccine-Related Research and Development” [hereinafter, Part One]. Following that review of the global literature and consultations with...
-
Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate
Download2014-10-24
Miller, Fiona A., Hogarth, Stuart, Evans, Jim, McCabe, Christopher, Pullman, Daryl, Joly, Yann, Szego, Michael J., Bubela, Tania, Fishman, Jennifer, Sankar, Pamela, Cook-Deegan, Robert, Biesecker, Barbara, Ravitsky, Vardit, Borry, Pascal, K. Cho, Mildred, Ungar, Wendy, J., Ossorio, Pilar, Kato, Kazuto, Wilson, Brenda, McGuire, Amy, Soo-Jin Lee, Sandra, Caulfield, Timothy, Rothenberg, Karen, Rousseau, Francois, Etchegary, Holly, Carroll, June C.
The cost of whole genome sequencing is dropping rapidly. There has been a great deal of enthusiasm about the potential for this technological advance to transform clinical care. Given the interest and significant investment in genomics, this seems an ideal time to consider what the evidence tells...
-
Value-Engineered Translation for Regenerative Medicine: Meeting the Needs of Health Systems
Download2014-10-29
McCabe, Christopher, Bubela, Tania
Despite high expectations of economic returns, large investments in regenerative medicine technology have yet to materialize, partly due to a lack of proven business and investment models, regulatory hurdles, and a greater focus on cost-effectiveness for reimbursement decisions by payors....